Shares of Check Cap Ltd (NASDAQ:CHEK) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus price target of $14.00 for the company and are forecasting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 88 out of 255 based on the ratings given to its competitors.
Several research firms have weighed in on CHEK. Zacks Investment Research lowered Check Cap from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. HC Wainwright set a $14.00 target price on Check Cap and gave the company a “buy” rating in a report on Wednesday, August 1st.
Check Cap stock traded down $0.09 during trading hours on Monday, hitting $3.85. The stock had a trading volume of 17,700 shares, compared to its average volume of 310,031. Check Cap has a 1-year low of $3.08 and a 1-year high of $23.88.
Check Cap (NASDAQ:CHEK) last posted its earnings results on Friday, August 10th. The medical research company reported ($0.70) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.12. Equities analysts predict that Check Cap will post -2.6 EPS for the current year.
An institutional investor recently bought a new position in Check Cap stock. Fosun International Ltd bought a new stake in Check Cap Ltd (NASDAQ:CHEK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 127,558 shares of the medical research company’s stock, valued at approximately $517,000. Fosun International Ltd owned about 7.97% of Check Cap as of its most recent filing with the Securities & Exchange Commission. 17.41% of the stock is owned by institutional investors.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Recommended Story: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.